Literature DB >> 21813598

Major histocompatibility complex class II transactivator CIITA is a viral restriction factor that targets human T-cell lymphotropic virus type 1 Tax-1 function and inhibits viral replication.

Giovanna Tosi1, Greta Forlani, Vibeke Andresen, Marco Turci, Umberto Bertazzoni, Genoveffa Franchini, Guido Poli, Roberto S Accolla.   

Abstract

Human T-cell lymphotropic virus type 1 (HTLV-1) is the causative agent of an aggressive malignancy of CD4+ T lymphocytes. Since the viral transactivator Tax-1 is a major player in T-cell transformation, targeting Tax-1 protein is regarded as a possible strategy to arrest viral replication and to counteract neoplastic transformation. We demonstrate that CIITA, the master regulator of major histocompatibility complex class II gene transcription, inhibits HTLV-1 replication by blocking the transactivating function of Tax-1 both when exogenously transfected in 293T cells and when endogenously expressed by a subset of U937 promonocytic cells. Tax-1 and CIITA physically interact in vivo via the first 108 amino acids of Tax-1 and two CIITA adjacent regions (amino acids 1 to 252 and 253 to 410). Interestingly, only CIITA 1-252 mediated Tax-1 inhibition, in agreement with the fact that CIITA residues from positions 64 to 124 were required to block Tax-1 transactivation. CIITA inhibitory action on Tax-1 correlated with the nuclear localization of CIITA and was independent of the transcription factor NF-YB, previously involved in CIITA-mediated inhibition of Tax-2 of HTLV-2. Instead, CIITA severely impaired the physical and functional interaction of Tax-1 with the cellular coactivators p300/CBP-associated factor (PCAF), cyclic AMP-responsive element binding protein (CREB), and activating transcription factor 1 (ATF1), which are required for the optimal activation of HTLV-1 promoter. Accordingly, the overexpression of PCAF, CREB, and ATF1 restored Tax-1-dependent transactivation of the viral long-terminal-repeat promoter inhibited by CIITA. These findings strongly support our original observation that CIITA, beside increasing the antigen-presenting function for pathogen antigens, acts as an endogenous restriction factor against human retroviruses by blocking virus replication and spreading.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813598      PMCID: PMC3187506          DOI: 10.1128/JVI.00813-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  The class II transactivator CIITA is a transcriptional integrator.

Authors:  J D Fontes; S Kanazawa; N Nekrep; B M Peterlin
Journal:  Microbes Infect       Date:  1999-09       Impact factor: 2.700

3.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements.

Authors:  Anna Kajaste-Rudnitski; Sara S Marelli; Cinzia Pultrone; Thomas Pertel; Pradeep D Uchil; Nadir Mechti; Walther Mothes; Guido Poli; Jeremy Luban; Elisa Vicenzi
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

5.  PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner.

Authors:  H Jiang; H Lu; R L Schiltz; C A Pise-Masison; V V Ogryzko; Y Nakatani; J N Brady
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

6.  Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes.

Authors:  C Spilianakis; J Papamatheakis; A Kretsovali
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300.

Authors:  T J Sisk; T Gourley; S Roys; C H Chang
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

8.  p300 and p300/cAMP-responsive element-binding protein associated factor interact with human T-cell lymphotropic virus type-1 Tax in a multi-histone acetyltransferase/activator-enhancer complex.

Authors:  R Harrod; Y L Kuo; Y Tang; Y Yao; A Vassilev; Y Nakatani; C Z Giam
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

Review 9.  TRIM family proteins and their emerging roles in innate immunity.

Authors:  Keiko Ozato; Dong-Mi Shin; Tsung-Hsien Chang; Herbert C Morse
Journal:  Nat Rev Immunol       Date:  2008-11       Impact factor: 53.106

Review 10.  The HTLV-1 Tax interactome.

Authors:  Mathieu Boxus; Jean-Claude Twizere; Sébastien Legros; Jean-François Dewulf; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2008-08-14       Impact factor: 4.602

View more
  20 in total

1.  CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.

Authors:  Elise Ramia; Anna Maria Chiaravalli; Farah Bou Nasser Eddine; Alessandra Tedeschi; Fausto Sessa; Roberto S Accolla; Greta Forlani
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

2.  The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein.

Authors:  Greta Forlani; Rawan Abdallah; Roberto S Accolla; Giovanna Tosi
Journal:  J Virol       Date:  2016-01-20       Impact factor: 5.103

Review 3.  Beyond the inflammasome: regulatory NOD-like receptor modulation of the host immune response following virus exposure.

Authors:  Sheryl Coutermarsh-Ott; Kristin Eden; Irving Coy Allen
Journal:  J Gen Virol       Date:  2016-01-13       Impact factor: 3.891

Review 4.  Highlights on distinctive structural and functional properties of HTLV Tax proteins.

Authors:  Maria Grazia Romanelli; Erica Diani; Elisa Bergamo; Claudio Casoli; Vincenzo Ciminale; Françoise Bex; Umberto Bertazzoni
Journal:  Front Microbiol       Date:  2013-09-09       Impact factor: 5.640

5.  The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells.

Authors:  Greta Forlani; Filippo Turrini; Silvia Ghezzi; Alessandra Tedeschi; Guido Poli; Roberto S Accolla; Giovanna Tosi
Journal:  J Transl Med       Date:  2016-04-18       Impact factor: 5.531

6.  Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL.

Authors:  Goutham U Raval; Carlo Bidoia; Greta Forlani; Giovanna Tosi; Antoine Gessain; Roberto S Accolla
Journal:  Retrovirology       Date:  2015-07-04       Impact factor: 4.602

7.  HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases.

Authors:  Marco Baratella; Greta Forlani; Roberto S Accolla
Journal:  Front Microbiol       Date:  2017-12-22       Impact factor: 5.640

8.  The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators.

Authors:  Greta Forlani; Rawan Abdallah; Roberto S Accolla; Giovanna Tosi
Journal:  Front Microbiol       Date:  2013-08-22       Impact factor: 5.640

9.  Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes.

Authors:  Massimiliano Bissa; Greta Forlani; Carlo Zanotto; Giovanna Tosi; Carlo De Giuli Morghen; Roberto S Accolla; Antonia Radaelli
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

10.  How Does HTLV-1 Undergo Oncogene-Dependent Replication Despite a Strong Immune Response?

Authors:  Hélène Gazon; Pradeep Chauhan; Malik Hamaidia; Clotilde Hoyos; Lin Li; Roghaiyeh Safari; Luc Willems
Journal:  Front Microbiol       Date:  2018-01-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.